<DOC>
	<DOCNO>NCT01673620</DOCNO>
	<brief_summary>The purpose study assess safety tolerability montelukast 10 mg/loratadine 10 mg versus placebo Mexican participant allergic rhinitis .</brief_summary>
	<brief_title>A Study Evaluate Safety Combination Montelukast/Loratadine Mexican Participants With Allergic Rhinitis ( MK-0476A-484 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Not pregnant breastfeeding plan become pregnant study 14day followup period Female participant reproductive potential agree remain abstinent use one acceptable method birth control least 14 day prior sign inform consent 14 day follow last visit History least 2 year seasonal allergic rhinitis symptom know flare local allergy season clinical history least 2 year perennial allergic rhinitis symptom persist year round For participant seasonal allergic rhinitis : positive skinprick test ( wheal &gt; = 3 mm great saline control ) one allergens active local allergy season positive radioallergosorbent test ( RAST [ define score &gt; = Class III ] ) For participant perennial allergic rhinitis : positive skin test ( wheal &gt; =3 mm great saline control ) one relevant perennial allergen positive RAST ( define score &gt; = Class III ) Nonsmoker nonsmoker least 1 year prior study Visit 1 smoke history 10 packyears ( 1 pack [ 20 cigarette ] per day 10 year ) Must good stable physical health mental health Hospitalization hospitalization within 4 week first schedule study visit Pregnancy within &lt; = 8 week postpartum breast feed Any major surgical procedure within 4 week first schedule study vist Current recent past abuser alcohol illicit drug Prior participation clinical trial montelukast loratadine within 4 week prior first schedule study visit Requires treatment inhale shortacting βagonist asthma ( e.g. , inhaled oral corticosteroid , theophylline , nedocromil , cromolyn , oral longacting inhaled βagonist , leukotriene receptor antagonist , leukotriene synthesis inhibitor ) and/or use 8 puff per day inhale shortacting βagonist Presence upper respiratory tract infection ( URI ) , sinusitis , infectious rhinitis ( symptom sore throat , fever , thick purulent rhinorrhea ) , ocular infection , history within 4 week prior first schedule study visit time study Visits 1 2 Other asthma , active , acute , chronic pulmonary disorder document history physical examination Rhinitis medicamentosa , nonallergic rhinitis Recent history ( within 3 month prior first schedule study visit ) clinically significant psychiatric disorder History anaphylactic reaction otherwise hypersensitive montelukast , loratadine , one component History current evidence general medical condition , concomitant therapy , lab abnormality circumstance might confound result study interfere patient 's participation full duration study History illness would require treatment excluded medication , could immediately life threatening ( ventricular arrhythmia , diabetes mellitus well control ) , would pose restriction participation successful completion study , would pose additional risk patient administer study drug History malignancy ≤5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>